Deal Snapshot: Approved in the EU/UK and nearing a US approval, rights to the RSV prophylaxis for infants and newborns are simplified in the pair of agreements unveiled by Synagis owner Sobi.
Who: Swedish Orphan Biovitrum AB/Sanofi/AstraZeneca
What: Sobi simplified its revenue streams tied to the respiratory syncytial virus candidate nirsevimab by inking a new US royalty...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Series B cash will be used to advance its Stargardt disease gene therapy.
